GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Retained Earnings

Satellos Bioscience (TSX:MSCL) Retained Earnings : C$-54.41 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Satellos Bioscience's retained earnings for the quarter that ended in Mar. 2024 was C$-54.41 Mil.

Satellos Bioscience's quarterly retained earnings declined from Sep. 2023 (C$-40.97 Mil) to Dec. 2023 (C$-47.50 Mil) and declined from Dec. 2023 (C$-47.50 Mil) to Mar. 2024 (C$-54.41 Mil).

Satellos Bioscience's annual retained earnings declined from Dec. 2021 (C$-20.29 Mil) to Dec. 2022 (C$-31.61 Mil) and declined from Dec. 2022 (C$-31.61 Mil) to Dec. 2023 (C$-47.50 Mil).


Satellos Bioscience Retained Earnings Historical Data

The historical data trend for Satellos Bioscience's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Retained Earnings Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Retained Earnings
-4.79 -20.29 -31.61 -47.50

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.28 -37.39 -40.97 -47.50 -54.41

Satellos Bioscience Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Satellos Bioscience  (TSX:MSCL) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Satellos Bioscience (TSX:MSCL) Business Description

Traded in Other Exchanges
Address
65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines